David Hollensbe
Urology · Carmel, INNPI 1841204625
Payments from drug & device makers
Across 91 payments — averaging $19.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$262
- AbbVie$194
- Antares Pharma, Inc.$162
- Boston Scientific$122
- Johnson & Johnson$88
- Sanofi-aventis U.S. LLC$85
- plus $879 from 23 others
What the payments were for
- Food & beverage$1,58688%
- Education$20712%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 13 | $262 |
| AbbVie(2 entities) | 12 | $194 |
| Antares Pharma, Inc. | 7 | $162 |
| Boston Scientific | 7 | $122 |
| Johnson & Johnson | 5 | $88 |
| Sanofi-aventis U.S. LLC | 1 | $85 |
| Sumitomo Pharma America, Inc. | 3 | $84 |
| Pfizer | 6 | $73 |
| Bayer | 3 | $61 |
| Accord Healthcare, Inc. | 3 | $60 |
| Alnylam Pharmaceuticals Inc. | 2 | $50 |
| Sanofi | 2 | $46 |
| Hollister Incorporated | 1 | $43 |
| Medtronic | 2 | $43 |
| Urovant Sciences Inc | 2 | $42 |
| Progenics Pharmaceuticals, Inc. | 2 | $39 |
| Travere Therapeutics, Inc. | 4 | $39 |
| AstraZeneca | 2 | $38 |
| Amgen | 2 | $32 |
| Laborie Medical Technologies Corp. | 2 | $31 |
| Merck | 1 | $28 |
| Ferring Pharmaceuticals Inc. | 1 | $28 |
| Blue Earth Diagnostics | 1 | $27 |
| Coloplast | 1 | $26 |
| Endo Pharmaceuticals Inc. | 2 | $25 |
| Sun Pharmaceutical Industries Inc. | 1 | $22 |
| Tolmar Pharmaceuticals, Inc. | 1 | $20 |
| Dendreon Pharmaceuticals LLC | 1 | $17 |
| Clarus Therapeutics Inc. | 1 | $6 |
How this compares
$1,793 in reported general payments places this provider in the 35th percentile of 272 urology providers in Indiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 30 | $29,066 |
| MyrbetriqMirabegron | 20 | $20,367 |
| Tamsulosin Hcl | 233 | $3,590 |
| Silodosin | 22 | $2,527 |
| Finasteride | 225 | $2,300 |
| Dutasteride | 34 | $981 |
| Solifenacin Succinate | 15 | $872 |
| Oxybutynin Chloride ErOxybutynin Chloride | 13 | $516 |
| Duloxetine Hcl | 20 | $450 |
| Testosterone Cypionate | 11 | $280 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 14 | $245 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $84 | $29,06630 claims |
| Astellas Pharma US IncMyrbetriq | $262 | $20,36720 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 272 urology providers in Indiana.
Other urology in Carmel
- Chad ReichardCarmel$1.3M
- Alexander TatemCarmel$441K
- Jason KovacCarmel$248K
- Matthew MellonCarmel$186K
- Kenneth NeyCarmel$102K
- Clinton BahlerCarmel$68K
- Jeremiah DallmerCarmel$52K
- Scott FarnhamCarmel$30K
- Megan BockCarmel$28K
- Ryan MaloneJeffersonville$7.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.